Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates.

Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 billion, according to Benzinga Pro. The company reported quarterly earnings of $2.11 per share, which beat analyst estimates of $2.06 per share.

Salesforce shares gained 9.4% to $252.00 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

Aditxt, Inc. ADTX shares rose 126.1% to $7.80 in pre-market trading.
Connexa Sports Technologies Inc. CNXA shares rose 74.7% to $0.5987 in pre-market trading. Connexa Sports recently reported a decline in sales for the second quarter.
Clearmind Medicine Inc. CMND rose 50.1% to $6.08 in pre-market trading after surging 22% on Wednesday. Clearmind Medicine recently announced results from its weight loss and metabolic disorder program.
Ampio Pharmaceuticals, Inc. AMPE shares surged 37.7% to $2.70 in pre-market trading after gaining over 3% on Wednesday.
Avenue Therapeutics, Inc. ATXI shares rose 33.4% to $0.2326 in pre-market trading after falling 8% on Wednesday. Robert Davidow reported a14.5 % passive stake in Avenue Therapeutics in a 13G Filing Tuesday.
Minim, Inc. MINM gained 29.3% to $1.19 in pre-market trading after gaining over 13% on Wednesday.
VinFast Auto Ltd. VFS gained 24.3% to $9.40 in pre-market trading after gaining around 8% on Wednesday.
Cyclacel Pharmaceuticals, Inc. CYCC shares climbed 18.5% to $0.3519 in pre-market trading. Cyclacel recently received notification of deficiency from Nasdaq regarding timely filing of quarterly report on form 10-Q.
Neumora Therapeutics Inc NMRA gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of NMRA-266 in healthy adult participants for schizophrenia and other neuropsychiatric disorders.

Losers

Vivos Therapeutics, Inc. VVOS dipped 32.9% to $27.51 in pre-market trading. Vivos Therapeutics shares jumped around 832% on Wednesday after the company announced it received FDA 510(k) clearance for treating severe obstructive sleep apnea in adults using the Vivos' removable CARE oral appliances.
RedHill Biopharma Ltd. RDHL shares fell 21.5% to $2.26 in pre-market trading after gaining 26% on Wednesday. On Monday, Redhill Biopharma announced that the FDA had granted five years' market exclusivity for its drug, Talicia, on top of three years' exclusivity granted for the approval of Talicia.
Nvni Group Limited NVNI shares fell 19.2% to $1.89 in pre-market trading after gaining over 5% on Wednesday.
Apollomics, Inc. APLM fell 18.5% to $0.92 in pre-market.
Yoshiharu Global Co. YOSH shares fell 16.2% to $7.72 in pre-market trading. Yoshiharu Global shares jumped 93% on Wednesday after the company effected a 1-for-10 reverse stock split for its Class A and Class B common stock.
Pure Storage, Inc. PSTG fell 15.7% to $31.95 in pre-market trading after the company reported worse-than-expected third-quarter revenue results and issued FY24 revenue guidance below estimates.
ProSomnus, Inc. OSA shares fell 15.6% to $0.7933 in pre-market trading after gaining 23% on Wednesday.
Pasithea Therapeutics Corp. KTTA shares fell 15.3% to $0.2997 in pre-market trading after gaining around 7% on Wednesday
C3is Inc. CISS fell 14% to $0.4555 in pre-market trading after jumping 21% on Wednesday.
Safe and Green Development Corporation SGD fell 10.4% to $2.37 in pre-market trading after dipping 14% on Wednesday.